Navigation Links
Pacira Pharmaceuticals, Inc. Announces Timing for First Quarter 2011 Financial Results Webcast and Conference Call

PARSIPPANY, N.J., May 4, 2011 /PRNewswire/ -- Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX), an emerging specialty pharmaceutical company, today announced that financial results for the company's first quarter ended March 31, 2011 will be released before the market opens on Wednesday, May 11, 2011. The Pacira management team will host a conference call to discuss the company's financial results and recent and upcoming developments on Wednesday, May 11, 2011 at 10 a.m. EDT. The call can be accessed by dialing 1-866-783-2143 (domestic) or 1-857-350-1602 (international) and providing the passcode 55610905. A replay of the call will be available approximately two hours after the completion of the call and can be accessed by dialing 1-888-286-8010 (domestic) or 1-617-801-6888 (international), and providing the passcode 69231212. The replay will be available for two weeks from the date of the live call.

The live, listen-only webcast of the conference call can be accessed by visiting the investors section of the company's website at A replay of the webcast will be archived on the Pacira website for two weeks following the call.

About Pacira

Pacira Pharmaceuticals, Inc. is an emerging specialty pharmaceutical company focused on the development, manufacture and commercialization of novel pharmaceutical products, based on its proprietary DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. In December 2010, Pacira announced that its New Drug Application (NDA) for EXPAREL, the company's most advanced investigational product candidate, had been accepted for filing by the U.S. Food and Drug Administration (FDA). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of July 28, 2011 for the review of the EXPAREL NDA. EXPAREL is a bupivacaine-based product and has completed extensive Phase 3 clinical development for postoperative analgesia by infiltration. EXPAREL consists of bupivacaine encapsulated in DepoFoam, which is designed to address the limitations of widely used medications by enhancing their dosing and/or administration profile. Additional information about Pacira is available at


James S. Scibetta
Chief Financial Officer
Pacira Pharmaceuticals, Inc.
(973) 254-3570

Jennifer Beugelmans
Vice President, Investor Relations
Pure Communications, Inc.
(646) 596-7473

SOURCE Pacira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pacira Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference
2. Pacira Pharmaceuticals Reports Fourth Quarter and 2010 Financial Results
3. Pacira Pharmaceuticals to Present at the Barclays Capital 2011 Global Healthcare Conference
4. Pacira Pharmaceuticals EXPAREL™ Data to be Featured at 2011 ASCPT 112th Annual Meeting
5. Pacira Pharmaceuticals Highlights Additional Safety Data on EXPAREL™ for Postsurgical Pain Relief at 2011 American Academy of Orthopaedic Surgeons Annual Meeting
6. Pacira Pharmaceuticals, Inc. Announces Pricing of Its Initial Public Offering
7. Pacira Pharmaceuticals Presents New Data from EXPAREL Phase 3 Study at Orthopaedic Research Societys 57th Annual Meeting
8. Pacira Pharmaceuticals Announces FDA Acceptance of EXPAREL™ New Drug Application for Pain Management
9. Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment
10. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Hernia Repair Presented at the Postgraduate Assembly in Anesthesiology (PGA)
11. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress
Post Your Comments:
(Date:11/30/2015)... Nov. 30, 2015 Booth #4303 – The Imaging ... will exhibit a broader array of products in a new ... of North America in ... meeting will feature X-ray components "At the Heart of Imaging." ... of products from Varian,s Claymount brand, and computer-aided diagnostic software ...
(Date:11/30/2015)... EAST HANOVER, N.J. , Nov. 30, 2015 /PRNewswire/ ... and portfolio at the 57 th American Society ... across leukemias, lymphomas and myelomas as well as supportive ... populations, in addition to personalized cell therapies. The ASH ... Orlando, Florida . Novartis Oncology ...
(Date:11/30/2015)... LONDON and BOSTON , ... to research and develop potential new medicines directed at ... multiple therapeutic areas. --> PFE ) to ... to 10 G protein-coupled receptor (GPCR) targets across multiple ... clinical-stage GPCR structure-guided drug discovery and development company and ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... A novel class ... could be effective in fighting methicillin-resistant Staphylococcus aureus (MRSA), one of the major ... showed that small molecule analogs that target the functions of SecA, a central ...
(Date:11/30/2015)... ... , ... Using a combination of two blood sugar tests rather than a ... a new study by researchers at the School of Public Health at Georgia State ... of Blood Glucose Tests ,” published in Frontiers in Public Health, the researchers noted ...
(Date:11/30/2015)... ... November 30, 2015 , ... International telepathology ... UPMC and KingMed Diagnostics researchers. Their review of more than ... with UPMC pathologists resulted in significantly altered treatment plans for more than half ...
(Date:11/30/2015)... ... November 30, 2015 , ... The Foundation for Breast and ... prevention—is joining forces with the award-winning creator and writer of Downton Abbey Julian ... 2015 at the Union League of Philadelphia. , The benefit, titled “An ...
(Date:11/30/2015)... ... November 30, 2015 , ... California-based i2i ... years, announced today that Michigan-based Family Health Center (FHC) has selected i2iTracks as ... years, FHC was awarded the largest Affordable Care Act grant for Federally Qualified ...
Breaking Medicine News(10 mins):